PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Lymecycline→

Lymecycline PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
992-21-2
Molecular formula
C29H38N4O10
Molecular weight
602.6 g/mol
Drug class
Tetracycline-class antibacterial antibiotic
Mechanism of action
Bacteriostatic agent that binds the bacterial 30S ribosomal subunit and prevents aminoacyl-tRNA access to the mRNA–ribosome complex, inhibiting protein synthesis. In acne, part of the effect is due to reduced growth of susceptible skin organisms and reduced free fatty acids in sebum.
Indications / reported uses
  • Moderate-to-severe acne vulgaris
  • Infections caused by tetracycline-sensitive organisms, including selected respiratory, urogenital (Chlamydia), soft-tissue and rickettsial infections; use is subject to official antimicrobial guidance and product-specific indication

Sources: UK SmPC — Lymecycline 408 mg capsules · UK SmPC — Tetralysal 300 mg capsules (updated 12 Aug 2026) · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Lymecycline PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Lymecycline Permitted Daily Exposure (PDE) report (the Lymecycline PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Lymecycline Occupational Exposure Limit (OEL) report (the Lymecycline OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.